{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    9,
    10,
    11,
    12,
    13,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28
  ],
  "modelUsed": "gemini-3-flash-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "Arm A: Avelumab + Axitinib",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Avelumab 10 mg/kg IV Q2W in a 6-week cycle + axitinib 5 mg PO BID continuously. Intrapatient axitinib dose escalation may occur if relevant criteria are met.",
        "extensionAttributes": [
          {
            "url": "x-titration",
            "valueString": "true"
          },
          {
            "url": "x-doseEpochs",
            "valueString": "[{'dose': 'Avelumab 10 mg/kg Q2W + Axitinib 5 mg BID', 'startDay': 1, 'description': 'Starting dose regimen; axitinib may be escalated based on safety/tolerability.'}]"
          }
        ]
      },
      {
        "id": "arm_2",
        "name": "Arm B: Sunitinib",
        "type": {
          "code": "Active Comparator Arm",
          "codeSystem": "USDM",
          "decode": "Active Comparator Arm"
        },
        "instanceType": "StudyArm",
        "description": "Sunitinib 50 mg PO QD on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off) in 6-week cycles."
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_2",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_2",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_5"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_2",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_6"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "PD-L1 Positive",
        "instanceType": "StudyCohort",
        "characteristic": "Patients with PD-L1 expression prospectively defined as positive"
      },
      {
        "id": "cohort_2",
        "name": "All Comers",
        "instanceType": "StudyCohort",
        "characteristic": "Patients unselected for PD-L1 expression"
      }
    ],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "Arm A: Avelumab + Axitinib - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm A: Avelumab + Axitinib during Screening"
      },
      {
        "id": "elem_2",
        "name": "Arm A: Avelumab + Axitinib - Study Treatment",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm A: Avelumab + Axitinib during Study Treatment"
      },
      {
        "id": "elem_3",
        "name": "Arm A: Avelumab + Axitinib - Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm A: Avelumab + Axitinib during Follow-up"
      },
      {
        "id": "elem_4",
        "name": "Arm B: Sunitinib - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm B: Sunitinib during Screening"
      },
      {
        "id": "elem_5",
        "name": "Arm B: Sunitinib - Study Treatment",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm B: Sunitinib during Study Treatment"
      },
      {
        "id": "elem_6",
        "name": "Arm B: Sunitinib - Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm B: Sunitinib during Follow-up"
      }
    ],
    "summary": {
      "armCount": 2,
      "cellCount": 6,
      "cohortCount": 2,
      "elementCount": 6
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Open Label",
        "codeSystem": "USDM",
        "decode": "Open Label"
      },
      "randomizationType": {
        "code": "Randomized",
        "codeSystem": "USDM",
        "decode": "Randomized"
      },
      "allocationRatio": {
        "ratio": "1:1"
      },
      "stratificationFactors": [
        "Eastern Cooperative Oncology Group Performance Status (ECOG PS) (0 vs. 1)",
        "Region (United States vs Canada/Western Europe vs the rest of the world)"
      ],
      "controlType": {
        "code": "Active Control",
        "codeSystem": "USDM",
        "decode": "Active Control"
      },
      "armIds": [
        "arm_1",
        "arm_2"
      ],
      "cohortIds": [
        "cohort_1",
        "cohort_2"
      ],
      "therapeuticAreas": [
        "Oncology",
        "Renal Cell Carcinoma"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Open Label",
        "maskedRoles": []
      },
      "randomization": {
        "type": "Randomized",
        "allocationRatio": "1:1",
        "stratificationFactors": [
          "Eastern Cooperative Oncology Group Performance Status (ECOG PS) (0 vs. 1)",
          "Region (United States vs Canada/Western Europe vs the rest of the world)"
        ]
      },
      "controlType": "Active Control",
      "therapeuticAreas": [
        "Oncology",
        "Renal Cell Carcinoma"
      ]
    },
    "arms": [
      {
        "name": "Arm A: Avelumab + Axitinib",
        "type": "Experimental Arm",
        "description": "Avelumab 10 mg/kg IV Q2W in a 6-week cycle + axitinib 5 mg PO BID continuously. Intrapatient axitinib dose escalation may occur if relevant criteria are met.",
        "isTitration": true,
        "doseEpochs": [
          {
            "dose": "Avelumab 10 mg/kg Q2W + Axitinib 5 mg BID",
            "startDay": 1,
            "endDay": null,
            "description": "Starting dose regimen; axitinib may be escalated based on safety/tolerability."
          }
        ]
      },
      {
        "name": "Arm B: Sunitinib",
        "type": "Active Comparator",
        "description": "Sunitinib 50 mg PO QD on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off) in 6-week cycles.",
        "isTitration": false,
        "doseEpochs": []
      }
    ],
    "cohorts": [
      {
        "name": "PD-L1 Positive",
        "characteristic": "Patients with PD-L1 expression prospectively defined as positive"
      },
      {
        "name": "All Comers",
        "characteristic": "Patients unselected for PD-L1 expression"
      }
    ],
    "epochs": [
      {
        "name": "Screening",
        "description": "Up to 28 days prior to randomization"
      },
      {
        "name": "Study Treatment",
        "description": "6-week cycles (42 days) until confirmed disease progression, unacceptable toxicity, or withdrawal"
      },
      {
        "name": "Follow-up",
        "description": "Includes safety reporting for 90 days after last dose and long-term survival follow-up"
      }
    ]
  }
}